STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Regulation FD Disclosure

On May 16, 2019 RA Medical Systems, Inc. (“RA”) filed a complaint (the “California Litigation”) in the United States District Court for the Southern District of California against Dr. Uri Geiger, Chairman of STRATA Skin Sciences, Inc., Accelmed Growth Partners, L.P. and STRATA Skin Sciences, Inc. (the “Company”).

In August 2018 STRATA and Dr. Geiger filed a Declaratory Judgement action against RA in the Court of Common Pleas, Montgomery County, Pennsylvania (the “Pennsylvania Action”). This matter was previously disclosed in its Current Report on Form 8-K dated August 30, 2018. On May 23, 2019, the Company and Dr. Geiger filed a Motion for Contempt in the Pennsylvania Action, against RA for RA’s willful violation of the Pennsylvania Court’s Confidentiality Order by using confidential information from the Pennsylvania Action in RA’s complaint in the California Litigation.

STRATA is asking the Pennsylvania Court to find RA in contempt of the Court’s Confidentiality Order and to require RA to compensate STRATA for the violation, including the payment of legal fees and precluding RA from utilizing any confidential information produced by Plaintiffs in any other forum.

A copy of the Motion for Contempt is submitted herewith as Exhibit 99.1, and a copy of the Brief in Support of the Motion is attached as Exhibit 99.2.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed \”filed\” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \”Exchange Act\”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits

STRATA Skin Sciences, Inc. Exhibit
EX-99.1 2 ex_99-1.htm MOTION FOR CONTEMPT & SANCTIONS EXHIBIT 99.1   STRATA SKIN SCIENCES,…
To view the full exhibit click here

About STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.